BACK
|Enrolling

Embrace UTI

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serotypes.

More Information

Capital Area Research LLC © Copyright 2024 All rights reserved.
875 Popular Church Rd. Suite 330 Camp Hill, PA - 717.963.8389